Shares in Roche Holding Ltd climbed 1.53% to CHF372.40 on Wednesday. The bullish outlook for the stock is now more closely connected to a broad range of sales projections for its breast cancer drug giredestrant.
Company hubSWX:RO
Follow the latest Roche (RO) company news, earnings coverage and investor analysis from TechStock².
| Measure | Value | CER | CHF |
|---|---|---|---|
| Group sales | 30.36bn | +6% | −2% |
| Pharma sales | 23.63bn | +6% | −1% |
| Diagnostics | 6.74bn | +3% | −3% |
| Core operating profit | 11.86bn | +10% | −1% |
| Core EPS | CHF10.85 | +9% | −2% |
| Company | P/E | EPS growth | Yield |
|---|---|---|---|
| Roche | 24.30× | +30.49% | 2.94% |
| Novartis | 24.18× | −11.50% | 2.95% |
| AstraZeneca | 24.18× | +21.16% | 2.08% |
| Novo Nordisk | 11.43× | +5.13% | 3.95% |
| View | Target | Rating |
|---|---|---|
| 18-analyst average | CHF363.92 | Buy |
| Bernstein | CHF434.50 | Outperform |
| Morgan Stanley | CHF410.00 | Overweight |
| UBS | CHF376.00 | Buy |
| Goldman Sachs | CHF365.00 | Neutral |
